You just read:

­­­­­­­­­Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at ASCO 2020 Annual Meeting

News provided by

Marker Therapeutics, Inc.

May 13, 2020, 17:01 ET